Skip to main content
Lineage Cell Therapeutics Inc. logo

Lineage Cell Therapeutics Inc. — Investor Relations & Filings

Ticker · LCTX ISIN · US53566P1093 LEI · 5299002BI4W22SDF8R25 TA Manufacturing
Open in API
Filings indexed 2,777 across all filing types
Latest filing 2025-11-09 Earnings Release
Country US United States of America
Listing TA LCTX

About Lineage Cell Therapeutics Inc.

https://lineagecell.com/

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic cell therapies for unmet medical needs. The company's proprietary platform uses directed differentiation of pluripotent stem cells to manufacture specialized human cells. These "off-the-shelf" cell transplants are designed to replace or support dysfunctional cells in patients with serious conditions, aiming to restore or enhance physiological function. The therapeutic pipeline is focused on degenerative diseases of the eye, such as dry age-related macular degeneration, and neurological conditions, including spinal cord injury. The company leverages its integrated capabilities in cell line development, manufacturing, and delivery to advance its programs.

Recent filings

Filing Released Lang Actions
Immediate Report
Earnings Release Classification · 100% confidence The document is a press release from Lineage Cell Therapeutics announcing their third quarter 2025 financial results. It includes key financial highlights (revenues, operating expenses, net loss), business updates, and information regarding an upcoming conference call. This fits the definition of an Earnings Release (ER), as it is the initial announcement of quarterly financial results containing key highlights rather than a full quarterly report or a transcript. Q3 2025
2025-11-09 English
Immediate Report
Report Publication Announcement Classification · 100% confidence The document is a short regulatory filing (under 2,100 characters) submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results' and provides a filename for the attachment. According to the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-11-09 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is Item 2.02, which states that the company issued a press release announcing financial results for the quarter ended September 30, 2025. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length is 3503 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing quarterly financial results via a press release is classified as an Earnings Release (ER).
2025-11-06 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-09-26 English
Regulatory Filings 2025
Regulatory Filings
2025-09-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.